Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Cambridge Biomedical COO Appointed to Board of Virogates
  • USA - English


News provided by

Cambridge Biomedical

Dec 04, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Cambridge Biomedical
Cambridge Biomedical

Boston (PRWEB) December 04, 2013 -- John J. Reddington, DVM, PhD, COO of Cambridge Biomedical Inc. and former CEO of Sirtex Medical Inc., to join ViroGates’ non-executive board.

ViroGates announced that John J. Reddington, Chief Operation Officer of Cambridge Biomedical Inc., was appointed to the company’s board of directors, increasing the number of board members to 7.

Your bioanalytical assay and clinical diagnostics source.

Post this

“John brings a wealth of experience, from raising capital and building productive relationships with investors to sales and marketing, as well as regulatory and reimbursement expertise related to the US diagnostics market, and we are delighted that he is joining ViroGates’s board of directors,” said Jakob Knudsen, CEO of ViroGates. “John joining the Board is in line with our increased focus on the US market.”

John R. Reddington currently serves as COO of Cambridge Biomedical Inc., a contract laboratory research organisation (CLIA) located in Boston, Ma., who supports the pharmaceutical, biopharmaceutical and medical device industries with assay development and validation of biomarkers, companion diagnostic and specimen analysis. Since 2011, John J. Reddington has been on the board of Directors at Pathology Experts, an early-stage privately held consulting firm, who service the histopathology, toxicology and preclinical research needs of Life Sciences companies in Europe and North America.

The new board member joins ViroGates at an exciting time. The company has just received notification from the European Patent Office that Patent application 07858108.9 Soluble urokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular disease will be granted. The Patent will be subject to national filing in the European countries, and will allow ViroGates protection of use of its suPARnostic® product range in the testing of healthy individuals to determine risk of development of cardiovascular disease, which is the leading cause of death worldwide. Furthermore ViroGates and Hvidovre Hospital have recently announced that suPARnostic has been implemented at the Danish Hospitals Acute Medical Ward.

"I am pleased and honoured to join the Board of Directors of ViroGates. I have been following the Company's progress over the last five years and have been very impressed by the success and professionalism of the organization in bringing its suPARnostic test to the global market. This diagnostic provides an important tool for the practicing physician to rapidly evaluate the health status of their patients," said John J. Reddington.

About Cambridge Biomedical
Since 1997, Cambridge Biomedical has provided a customer focused approach to support our clients by providing a diverse range of bioanalytical services from pre-clinical to post market. These include assay development, optimization, validation and diagnostic testing. Conveniently located in Boston to support the North East pharmaceutical development market, yet with a national and global reach. We deliver personalized project management and rapid turnaround times to expedite your development pipeline.

Contact: 1320 Soldiers Field Road Boston, MA 02135 T: 617.456.0700 salesinfo(at)cambridgebiomedical(dot)com

About ViroGates
ViroGates is an international MedTech company headquartered in Copenhagen, Denmark. ViroGates develops and distributes prognostic products for healthcare management. The novel ViroGates products labelled suPARnostic®, measures a protein known as soluble urokinase Plasminogen Activator Receptor (suPAR). In clinical practice, suPAR’s main application is screening of individuals to determine the risk of disease progression of the patient. The suPARnostic® product range has been tested in more than 150,000 patient samples and results have been published in more than 250 accredited journals. suPARnostic®’s prognostic value has been documented in various infectious conditions via clinical studies, these include acute care, sepsis, tuberculosis, malaria and HIV but also in inflammatory diseases such as cardiovascular diseases and type-2 diabetes. The first commercial suPARnostic® product was an ELISA-based test kit for the quantitative determination of suPAR in human plasma. The novel suPARnostic® Quick Triage product is a simple lateral flow device that is based on human plasma to assess the disease severity of the patients in need of a fast response, typically when entering the hospital system (acute care). ViroGates has launched the suPARnostic® products in Europe, Africa and Canada.

Further Information
Please contact: Jakob Knudsen, CEO ViroGates (+45 2226 1355 or jk(at)virogates(dot)com) – http://www.virogates.com

Bob Evans, Cambridge Biomedical, http://www.cambridgebiomedical.com, +1 (617) 456-0752, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.